Coeptis Therapeutics Holdings Inc. Common Stock (COEP)

FairStock Score: 42/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor, I start with the business, not the story. Coeptis is a four-employee biopharmaceutical company pursuing cell therapies, including an allogeneic platform and DVX201. It was acquired by Z Squared in a reverse merger as of April 24, 2026, so the corporate history is short and the Lynch category is none because there are only zero years of filed results needed for three. In the fourth quarter of 2025, revenue was $862,049 and net income was -$1.6 million, a -183.04% margin. Trailing free cash flow was -$8.6 million, a FairStock FCF yield of -8.6% based on the 2026-04-24 close. EPS is -$2.81, and based on the 2026-04-24 close, FairStock calculations show a P/E of -5.84 and a P/B of 6.95. Those are not Graham-style bargains; they reflect a company whose value rests on unproven pipeline hopes, not on earnings or assets. FairStock return metrics are deeply negative: ROE -136.91% and ROCE -65.05%. The balance sheet shows low leverage with D/E 0.02, and FairStock's Altman Z-score of 19.21 is high, suggesting balance-sheet risk may be less immediate, but cash burn remains the enemy. FairStock's Piotroski F-Score is 5/9, and the FairStock score is 42/100. Listed profit growth of 19.00% may be an improvement from a negative base, but revenue growth is N/A. The 52-week range of $9.78 to $21.41 shows volatility. Without a durable moat, recurring revenue, or positive free cash flow, I would not call this a business with a margin of safety. It is a speculative clinical-stage story.

In plain English: Coeptis Therapeutics is a very small biopharmaceutical company developing cell therapies for cancer, autoimmune and infectious diseases; it was acquired by Z Squared in a reverse merger on April 24, 2026. The business looks weak today because it has very little revenue, is losing money, and burns cash. At $16.40, the price does not look cheap compared with the company's current sales and losses, though a clinical-stage company is often valued on future prospects rather than today's numbers.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-04-24 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer